The Preferred Biotech Resource in Asia-Pacific
Vol 19, No 07, July 2015
Biotech in China
Kh-biotech cover

Featured
Interviews

Eye on China

Columns

Conferences ListingConferences
Listing

e-alerts
Pharma Sales
INSIDE INDUSTRY
Alchemia announces multi-target drug discovery collaboration with AstraZeneca on VAST discovery platform
Alchemia Limited, a drug discovery and development company, announced that it has signed a multi-target, drug discovery collaboration with AstraZeneca AB.

This collaboration includes the use of the proprietary Diversity Scanning Array (DSA) and associated Versatile Assembly on Stable Templates (VAST) chemistry platform to discover and develop novel small molecules against multiple AstraZeneca targets. Alchemia will provide VAST chemistry expertise to develop small molecule clinical candidates for AstraZeneca. By accessing Alchemia’s VAST discovery platform, AstraZeneca will seek novel small molecules to treat diseases across a variety of therapeutic areas including oncology, respiratory, cardiovascular, metabolism, infection and neuroscience.

“We are excited to work alongside AstraZeneca’s teams to explore the applications of our proprietary VAST technology against a range of targets,” said Dr. Wim Meutermans, VP of Discovery at Alchemia and co-inventor of the VAST platform.

“This collaboration has the potential to demonstrate the unique capabilities and value of VAST and is a pivotal step in the commercialization of both the DSA and the VAST platform. I look forward to developing a strong and productive alliance with AstraZeneca over the coming years.”

“Alchemia’s DSA library and expertise in carbohydrate chemistry are welcome additions to our small molecule corporate collection and early discovery hit finding activities,” said Mike Snowden, Head of Discovery Sciences at AstraZeneca. “We are looking forward to working with Alchemia to maximize the potential of this novel platform in early phase drug discovery at AstraZeneca.”

Under the terms of this Agreement, Alchemia will receive an undisclosed upfront payment and is eligible for potential preclinical, clinical and commercial launch payments totaling up to $240M, as well as a single digit royalty.

Click here for the complete issue.